AZNAstraZenecaRunning, no new patients
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
Hepatocellular Carcinoma
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Sep 2023, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 724 (final count)
- Started
- Nov 30, 2018
- Main results expected
- Sep 11, 2023
- Fully finished
- Aug 31, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) for Arm B vs Arm C
Measured over: Approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2023-09-11, no fading
Raw record changes
- none yet
Trial ID NCT03778957 · record last updated 2026-07-15 · checked 2026-11-09 15:47 UTC